Hypoxia potentiates glioma-mediated immunosuppression

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Wei, Jun ^a   Wu, Adam ^a   Kong, Ling Yuan ^a   Wang, Yongtao ^a   Fuller, Gregory ^a   Fokt, Isabella ^a   Melillo, Giovanni ^b   Priebe, Waldemar ^a   Heimberger, Amy B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VASCULOTROPIN; WP 1066; WP 744; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG POTENCY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; PHAGOCYTOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANOXIA; CANCER STEM CELL; CELL PROLIFERATION; GLIOMA; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; T LYMPHOCYTE; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT;

ANOXIA; CELL PROLIFERATION; GLIOBLASTOMA; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; NEOPLASTIC STEM CELLS; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79251620102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016195     Document Type: Article

References (58)

1. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, et al. (2010) Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 16: 800-813.
2. Wei J, Barr J, Kong LY, Wang Y, Wu A, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 9: 67-78.
3. Wei J, Barr J, Kong LY, Wang Y, Wu A, et al. Glioma-associated cancerinitiating cells induce immunosuppression. Clin Cancer Res 16: 461-473.
4. Wu A, Wei J, Kong LY, Wang Y, Priebe W, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol.
5. Brown CE, Starr R, Martinez C, Aguilar B, D'Apuzzo M, et al. (2009) Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res 69: 8886-8893.
6. Pellegatta S, Poliani PL, Corno D, Menghi F, Ghielmetti F, et al. (2006) Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 66: 10247-10252.
7. Xu Q, Liu G, Yuan X, Xu M, Wang H, et al. (2009) Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 27: 1734-1740.
8. Jensen RL (2009) Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 92: 317-335.
9. Carmeliet P, Dor Y, Herbert J-M, Fukumuras D, Brusselmans K, et al. (1998) Role of HIF-1a in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-480.
10. Ben-Shoshan J, Maysel-Auslender S, Mor A, Keren G, George J (2008) Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol 38: 2412-2418.
11. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, et al. (2005) HIF-1a, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24: 3110-3120.
12. Jung JE, Lee HG, Cho IH, Chung DH, Yoon S-H, et al. (2005) STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 19: 1296-1298.
13. Johnson B, Osada T, Clay T, Lyerly H, Morse M (2009) Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr Mol Med 9: 702-707.
14. Johnson BF, Clay TM, Hobeika, Kim Lyerly HK, Morse MA (2007) Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther 7: 449-460.
15. Biollaz G, Bernasconi L, Cretton C, Puntener U, Frei K, et al. (2009) Sitespecific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol 39: 1323-1333.
16. Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, et al. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol 12: 7-13.
17. Maeda H, Kuwahara H, Ichimura Y, Ohtsuki M, Kurakata S, et al. (1995) TGF-beta enhances macrophage ability to produce IL-10 in normal and tumorbearing mice. J Immunol 155: 4926-4932.
18. Lucas T, Abraham D, Aharinejad S (2008) Modulation of tumor associated macrophages in solid tumors. Front Biosci 13: 5580-5588.
19. Pixley FJ, Stanley ER (2004) CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 14: 628-638.
20. Brault MS, Kurt RA (2005) Impact of Tumor-Derived CCL2 on Macrophage Effector Function. J Biomed Biotechnol 2005: 37-43.
21. Conti I, Rollins BJ (2004) CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 14: 149-154.
22. Kuklinski S, Pesheva P, Heimann C, Urschel S, Gloor S, et al. (2000) Expression pattern of galectin-3 in neural tumor cell lines. Journal of Neuroscience Research 60: 45-57.
23. Peng W, Wang HY, Miyahara Y, Peng G, Wang RF (2008) Tumor-associated galectin-3 modulates the function of tumor-reactive T cells. Cancer Res 68: 7228-7236.
24. Carroll VA, Ashcroft M (2006) Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 66: 6264-6270.
25. Knowles HJ, Athanasou NA (2008) Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol 215: 56-66.
26. Lin EY, Li JF, Gnalovskiy L, Deng Y, Zhu L, et al. (2006) Macrophages regulate the angiogenic switch in amouse model of breast cancer. Cancer Res 66: 11238-11246.
27. Sarwat AM, Al-Salam S (2009) Expression of HIF-1, galectin-3, cox-2 and Wilms tumor-1 protein in multiple schwannomas of the conus medullaris. J Neurooncol 92: 111-115.
28. Tabatabai G, Frank B, Mohle R, Weller M, Wick W (2006) Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. Brain 129: 2426-2435.
29. O'Farrell AM, Liu Y, Moore KW, Mui AL (1998) IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: Evidence for Stat3-dependent and independent pathways. EMBO J 17: 1006-1018.
30. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, et al. (2006) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 12: 1314-1321.
31. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, et al. (2006) The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8: 261-279.
32. Kostianovsky AM, Maier LM, Anderson RC, Bruce JN, Anderson DE (2008) Astrocytic regulation of human monocytic/microglial activation. J Immunol 181: 5425-5432.
33. Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275-290.
34. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
35. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumor-associated macrophages. Immunol Today 13: 265-270.
36. Keith B, Simon MC (2007) Hypoxia-induced factors, stem cells, and cancer. Cell 129: 465-472.
37. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, et al. (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1a. Oncogene 28: 3949-3959.
38. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, et al. (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26: 2435-2444.
39. Estrov FS, H.M. K, Harris D, Van Q, Fokt I, et al. (2001) WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res 21: 3777-3784.
40. Lee K, D.Z. Q, Rey S, Wei H, Liu JO, et al. (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A 106: 2353-2358.
41. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
42. Hussain SF, Kong L-Y, Jordan J, Conrad C, Madden T, et al. (2007) A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67: 9630-9636.
43. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, et al. (2008) A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14: 5759-5768.
44. Sitkovsky M (2009) T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends in Immunology 30: 102-108.
45. Ohta A, Sitkovsky M (2001) Role of G-protein coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414: 916-920.
46. Leek RD, Landers RJ, Harris AL, Lewis CE (1999) Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 79: 991.
47. Murdoch C, Giannoudis A, Lewis CE (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104: 2224.
48. Negus RP, Stamp GW, Hadley J, Balkwill FR (1997) Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150: 1723.
49. Grimshaw MJ, Wilson JL, Balkwill FR (2002) Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol 32: 2393.
50. Barleon B, Sozzani S, Zhou D, Welch HA, Mantovani A, et al. (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336.
51. Acosta-Iborra B, Elorza A, Olazabal IM, Martin-Cofreces NB, Martin-Puig S, et al. (2009) Macrophage oxygen sensing modulates antigen presentation and phagocytic functions involving IFN-gamma production through the HIF-1 alpha transcription factor. J Immunol 182: 3155-3164.
52. Anand RJ, Gribar SC, Li J, Kohler JW, Branca MF, et al. (2007) Hypoxia causes an increase in phagocytosis by macrophages in a HIF-1alpha-dependent manner. J Leukoc Biol 82: 1257-1265.
53. Owegi HO, Egot-Lemaire S, Waite LR, Waite GN (2010) Macrophage activity in response to steady-state oxygen and hydrogen peroxide concentration-biomed 2010. Biomed Sci Instrum 46: 57-62.
54. Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166.
55. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, et al. (2004) Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 22: 657-682.
56. Murdoch C, Lewis CE (2005) Macrophage migration and gene expression in response to tumore hypoxia. Int J Cancer 117: 701-708.
57. Jordan JT, Sun WH, Hussain SF, DeAngulo G, Prabhu SS, et al. (2008) Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57: 123-131.
58. Bodor J, Fehervari Z, Diamond B, Sakaguchi S (2007) ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur J Immunol 37: 884-895.